[Research Progress on Risk Factors and Intervention Measures for Prolonged Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation --Review].

Prolonged thrombocytopenia (PT) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), with an incidence of about 5%-37%, which is closely related to the poor prognosis of patients. Previous studies have shown that transplantation type, CD34+ cell number, pretreatment regimen, acute graft-versus-host disease, virus infection, pre-transplantation serum ferritin level and donor specific antibodies can affect platelet implantation after transplantation. Identifying the risk factors of PT is helpful to early identify high-risk patients and take targeted preventive measures according to different risk factors to reduce the incidence of PT, reduce the risk of bleeding and improve the prognosis of patients. This article reviews the latest research progress of risk factors and intervention measures related to PT after allo-HSCT, in order to provide reference for the prevention and treatment of PT after transplantation.异基因造血干细胞移植后血小板减少的危险因素及干预措施研究进展.持续性血小板减少(PT)是异基因造血干细胞移植(allo-HSCT)后常见并发症，其发生率约5%-37%，与患者预后不良密切相关。既往研究表明移植类型、CD34+细胞数量、预处理方案、急性移植物抗宿主病、病毒感染、移植前血清铁蛋白水平和供者特异性抗体等均可影响移植后血小板植入。明确PT的危险因素有助于早期识别高危患者并根据不同危险因素采取针对性预防措施以减少PT发生，降低出血风险，改善患者预后。本文就allo-HSCT后PT相关危险因素及干预措施的最新研究进展作一综述，以期为移植后PT的预防及治疗提供参考。.